Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States
Abstract Background Immune checkpoint inhibitors targeting the programmed cell death protein‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) axis (collectively referred to as PD[L]1i) have demonstrated clinical benefits in non‐small cell lung cancer (NSCLC) patients. The purpose of this United States...
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Wiley
2022-11-01
|
| سلاسل: | Cancer Medicine |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1002/cam4.4785 |